Human methylome studies SRP006774 Track Settings
 
Increased methylation variation in epigenetic domains across cancer types

Track collection: Human methylome studies

+  All tracks in this collection (463)

Maximum display mode:       Reset to defaults   
Select views (Help):
AMR       CpG reads ▾       CpG methylation ▾       PMD       HMR      
Select subtracks by views and experiment:
 All views AMR  CpG reads  CpG methylation  PMD  HMR 
experiment
SRX062397 
SRX062398 
SRX062399 
SRX062400 
SRX062401 
SRX062402 
SRX062403 
SRX062404 
List subtracks: only selected/visible    all    ()
  experiment↓1 views↓2   Track Name↓3  
hide
 SRX062397  HMR  SRS193045 / SRX062397 (HMR)   Schema 
hide
 Configure
 SRX062397  CpG methylation  SRS193045 / SRX062397 (CpG methylation)   Schema 
hide
 Configure
 SRX062398  CpG methylation  SRS193046 / SRX062398 (CpG methylation)   Schema 
hide
 SRX062399  HMR  SRS193047 / SRX062399 (HMR)   Schema 
hide
 SRX062401  HMR  SRS193049 / SRX062401 (HMR)   Schema 
hide
 Configure
 SRX062399  CpG methylation  SRS193047 / SRX062399 (CpG methylation)   Schema 
hide
 Configure
 SRX062400  CpG methylation  SRS193048 / SRX062400 (CpG methylation)   Schema 
hide
 Configure
 SRX062401  CpG methylation  SRS193049 / SRX062401 (CpG methylation)   Schema 
hide
 Configure
 SRX062402  CpG methylation  SRS193050 / SRX062402 (CpG methylation)   Schema 
hide
 Configure
 SRX062403  CpG methylation  SRS193051 / SRX062403 (CpG methylation)   Schema 
hide
 Configure
 SRX062404  CpG methylation  SRS193052 / SRX062404 (CpG methylation)   Schema 
    

Study title: Increased methylation variation in epigenetic domains across cancer types
SRA: SRP006774
GEO: not found
Pubmed: not found

Experiment Label Methylation Coverage HMRs HMR size AMRs AMR size PMDs PMD size Conversion Details
SRX062397 SRS193045 0.691 3.6 28179 1987.8 36 1141.3 482 58859.7 0.972 title: Whole-genome bisulfite SOLiD 3+ sequencing of normal colonic mucosa 1 of 3; {}
SRX062398 SRS193046 0.627 3.6 28665 4107.9 43 1083.8 257 3121135.8 0.970 title: Whole-genome bisulfite SOLiD 3+ sequencing of colorectal cancer 1 of 3; {}
SRX062399 SRS193047 0.698 3.3 28137 1944.1 16 1099.9 509 57684.8 0.969 title: Whole-genome bisulfite SOLiD 3+ sequencing of normal colonic mucosa 2 of 3; {}
SRX062400 SRS193048 0.587 3.0 26795 7507.6 29 1057.7 543 2021061.3 0.970 title: Whole-genome bisulfite SOLiD 3+ sequencing of colorectal cancer 2 of 3; {}
SRX062401 SRS193049 0.670 3.4 25389 2092.1 41 1065.0 364 34677.0 0.967 title: Whole-genome bisulfite SOLiD 3+ sequencing of normal colonic mucosa 3 of 3; {}
SRX062402 SRS193050 0.546 3.4 13310 20132.0 48 1114.6 1246 1105556.9 0.968 title: Whole-genome bisulfite SOLiD 3+ sequencing of colorectal cancer 3 of 3; {}
SRX062403 SRS193051 0.638 2.7 23679 2476.6 49 1169.3 80 226679.3 0.954 title: Whole-genome bisulfite SOLiD 3+ sequencing of adenomatous polyp 1 of 2; {}
SRX062404 SRS193052 0.588 2.9 27041 5927.3 36 1140.9 545 1736801.3 0.967 title: Whole-genome bisulfite SOLiD 3+ sequencing of adenomatous polyp 2 of 2; {}

Methods

All analysis was done using a bisulfite sequnecing data analysis pipeline DNMTools developed in the Smith lab at USC.

Mapping reads from bisulfite sequencing: Bisulfite treated reads are mapped to the genomes with the abismal program. Input reads are filtered by their quality, and adapter sequences in the 3' end of reads are trimmed. This is done with cutadapt. Uniquely mapped reads with mismatches/indels below given threshold are retained. For pair-end reads, if the two mates overlap, the overlapping part of the mate with lower quality is discarded. After mapping, we use the format command in dnmtools to merge mates for paired-end reads. We use the dnmtools uniq command to randomly select one from multiple reads mapped exactly to the same location. Without random oligos as UMIs, this is our best indication of PCR duplicates.

Estimating methylation levels: After reads are mapped and filtered, the dnmtools counts command is used to obtain read coverage and estimate methylation levels at individual cytosine sites. We count the number of methylated reads (those containing a C) and the number of unmethylated reads (those containing a T) at each nucleotide in a mapped read that corresponds to a cytosine in the reference genome. The methylation level of that cytosine is estimated as the ratio of methylated to total reads covering that cytosine. For cytosines in the symmetric CpG sequence context, reads from the both strands are collapsed to give a single estimate. Very rarely do the levels differ between strands (typically only if there has been a substitution, as in a somatic mutation), and this approach gives a better estimate.

Bisulfite conversion rate: The bisulfite conversion rate for an experiment is estimated with the dnmtools bsrate command, which computes the fraction of successfully converted nucleotides in reads (those read out as Ts) among all nucleotides in the reads mapped that map over cytosines in the reference genome. This is done either using a spike-in (e.g., lambda), the mitochondrial DNA, or the nuclear genome. In the latter case, only non-CpG sites are used. While this latter approach can be impacted by non-CpG cytosine methylation, in practice it never amounts to much.

Identifying hypomethylated regions (HMRs): In most mammalian cells, the majority of the genome has high methylation, and regions of low methylation are typically the interesting features. (This seems to be true for essentially all healthy differentiated cell types, but not cells of very early embryogenesis, various germ cells and precursors, and placental lineage cells.) These are valleys of low methylation are called hypomethylated regions (HMR) for historical reasons. To identify the HMRs, we use the dnmtools hmr command, which uses a statistical model that accounts for both the methylation level fluctations and the varying amounts of data available at each CpG site.

Partially methylated domains: Partially methylated domains are large genomic regions showing partial methylation observed in immortalized cell lines and cancerous cells. The pmd program is used to identify PMDs.

Allele-specific methylation: Allele-Specific methylated regions refers to regions where the parental allele is differentially methylated compared to the maternal allele. The program allelic is used to compute allele-specific methylation score can be computed for each CpG site by testing the linkage between methylation status of adjacent reads, and the program amrfinder is used to identify regions with allele-specific methylation.

For more detailed description of the methods of each step, please refer to the DNMTools documentation.